Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its price target raised by analysts at HC Wainwright from $80.00 to $85.00. They now have a "buy" rating on the stock.
Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe Hypertriglyceridemia
Arrowhead Pharmaceuticals to Participate in Upcoming December 2025 Conferences
Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its price target raised by analysts at Bank of America Corporation from $42.00 to $62.00. They now have a "buy" rating on the stock.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $60.00 price target on the stock.